Humanized antibody-drug conjugates for SSTR2-positive tumor treatment
RNA-seq (gene expression) · human · 10 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 10 samples: 5 × CH157-MN Control vs 5 × CH157-MN TreatmentGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE304978_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1303643 and SRA study SRP607752. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 10 samples.
How we read this: 2 replicated groups read from 10 sample titles; they account for 10 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9160546 CH157-MN Control Rep1 CH157-MN Control
- GSM9160547 CH157-MN Control Rep2 CH157-MN Control
- GSM9160548 CH157-MN Control Rep3 CH157-MN Control
- GSM9160549 CH157-MN Control Rep4 CH157-MN Control
- GSM9160550 CH157-MN Control Rep5 CH157-MN Control
- GSM9160551 CH157-MN Treatment Rep1 CH157-MN Treatment
- GSM9160552 CH157-MN Treatment Rep2 CH157-MN Treatment
- GSM9160553 CH157-MN Treatment Rep3 CH157-MN Treatment
- GSM9160554 CH157-MN Treatment Rep4 CH157-MN Treatment
- GSM9160555 CH157-MN Treatment Rep5 CH157-MN Treatment
- GSE260674 Effect of CD19-CD28 and glofitamab treatments in vivo on the RNA-Seq profile in tumor tissue from humanized mice over time 45 samples shares humanized, treatment
- GSE298420 Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1 (RNA-Seq of HuCC-A1 CDX tumors short treatment) 12 samples shares humanized, treatment
- GSE261998 Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1(HuCC-A1 CDX tumors) 10 samples shares humanized, treatment
- GSE261999 Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1(PDX tumors) 8 samples shares humanized, treatment
- GSE229723 Single cell RNA sequencing (scRNA-seq) data on the human CD45+ cells and tumor cells collected from four different treatment groups of hCD34+ humanized mice with human TNBC xenografic tumor model (mixed sample, non-demultiplexed) 2 samples shares humanized, treatment
- GSE267855 NF1 modulates microtubular repair and dictates sensitivity to maytansinoid antibody-drug conjugates in HER2-positive breast cancer 18 samples shares antibody-drug, conjugates
- GSE269495 SNX10 deficiency confers resistance to anti-HER2 antibody-drug conjugates via regulating endosomal trafficking 13 samples shares antibody-drug, conjugates
- GSE272989 MUC1-C DEPENDENCY IN DRUG RESISTANT HR+/HER2- BREAST CANCER IDENTIFIES A NEW TARGET FOR TREATMENT WITH AN ANTIBODY-DRUG CONJUGATE 12 samples shares antibody-drug, treatment
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.